Stellantis Joins GlobalPlatform to Advance Global Automotive Cybersecurity Standards
4.9.2025 16:00:00 EEST | Business Wire | Press release
Stellantis is the latest major auto OEM to join GlobalPlatform, helping to accelerate cross-industry collaboration on cybersecurity standardization for software-defined vehicles (SDVs).
Stellantis—the company behind 14 major auto brands, including Alfa Romeo, Chrysler, FIAT, Jeep®, Opel, Peugeot, and Vauxhall—has joined GlobalPlatform to help align its technologies with evolving automotive use cases and regulatory requirements. As part of the agreement, Bill Mazzara, North American Regulatory Lead and Technical Fellow for Product Cybersecurity at Stellantis, becomes co-chair of the GlobalPlatform Automotive Task Force.
Stellantis joins a growing community of automakers, cybersecurity firms, silicon vendors, and academic institutions in GlobalPlatform that are advancing a standardized approach to meeting the complex cybersecurity demands of today’s SDVs. Recent members of the Automotive Task Force include AIST, Cariad (Volkswagen), Dekra, ETAS, Linaro, Rambus, Renesas, Stellantis, Uni-sentry, and Woven by Toyota.
“GlobalPlatform’s Automotive Task Force is helping the industry converge on a platform of secure, scalable foundations for software-defined vehicles,” said Bill Mazzara. “Our engagement is focused on harmonizing security standards and fostering cross-industry collaboration to meet evolving regulatory and operational requirements and ultimately our customers' expectations.”
The Automotive Task Force is at the forefront of bringing market-proven GlobalPlatform technologies and specifications to the automotive sector. It recently reached a major milestone by fully aligning these specifications with the new addendum of the SAE J3101 Hardware Protected Security Environment automotive cybersecurity standard (J3101-5). This creates the formal means for GlobalPlatform-compliant suppliers to demonstrate automatic compliance with J3101. It provides automakers with confidence that components embedded in their vehicles meet cybersecurity requirements and facilitate integration with applications of AutoSAR, Car Connectivity Consortium, and other automotive frameworks.
The Automotive Task Force has also developed a protection profile based on the SESIP evaluation methodology to ensure component-level certifications are aligned with SAE J3101. This allows certified components to be reused across platforms without the need for re-evaluation, saving time and resources across the supply chain.
“Stellantis’ participation in GlobalPlatform reflects our commitment to advancing standardized, secure technologies that can scale across the automotive ecosystem,” said Muttalip Akin, SVP, Head of Electrical, Electronic & Hardware Engineering, Stellantis.
“These recent advancements represent a breakthrough in the industry’s goal of creating a standardized and certified platform for secure vehicle applications,” said Ana Tavares Lattibeaudiere, Executive Director, GlobalPlatform. “We urge further companies from across the auto industry to join us in our mission to lower risk, reduce costs, and eliminate fragmentation across the automotive cybersecurity ecosystem.”
About GlobalPlatform
GlobalPlatform is a technical standards organization that enables the efficient launch and management of innovative, secure-by-design digital services and devices. GlobalPlatform technologies are used in billions of smart cards, smartphones, wearables and other connected and IoT devices.
GlobalPlatform standardized technologies and certifications are developed through effective industry-driven collaboration, led by multiple diverse member companies working in partnership with industry and regulatory bodies and other interested parties from around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250828443903/en/
Contacts
For further media information:
Matt Ablott
mablott@combustion.marketing
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom